Evidence map›Paper›PMID 38888098›Full record

ReviewExpert review of vaccines

Immune mechanisms targeting malaria transmission: opportunities for vaccine development.

Geetha P Bansal, Nirbhay Kumar

Abstract readReview
In one paragraph

Review in Expert review of vaccines. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Molecular mechanisms involved inFrontiers in microbiology · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Geetha P BansalDepartment of Tropical Medicine, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
Nirbhay KumarDepartment of Global Health, The Milken Institute School of Public Health, George Washington University, Washington, DC, USA.

Funding

A DNA VACCINE TO PREVENT TRANSMISSION OF HUMAN MALARIAR01AI047089 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KUMAR, NIRBHAY · 2000 to 2011
$3.6M
Combination Vaccines to Interrupt Malaria TransmissionR01AI127544 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KUMAR, NIRBHAY · 2017 to 2020
$2.2M
Identification of Transmission blocking epitopes on P. vivax 48/45 proteinR03AI111138 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KUMAR, NIRBHAY · 2015 to 2016
$151k
NIAID NIH HHS R01 AI047089NIAID NIH HHS R01 AI127544NIAID NIH HHS R03 AI111138
6 · The paper itself

Abstract

introductionMalaria continues to remain a major global health problem with nearly a quarter of a billion clinical cases and more than 600,000 deaths in 2022. There has been significant progress toward vaccine development, however, poor efficacy of approved vaccines requiring multiple immunizing doses emphasizes the need for continued efforts toward improved vaccines. Progress to date, nonetheless, has provided impetus for malaria elimination. AREAS COVERED: In this review we will focus on diverse immune mechanisms targeting gametocytes in the human host and gametocyte-mediated malaria transmission via the mosquito vector. EXPERT OPINION: To march toward the goal of malaria elimination it will be critical to target the process of malaria transmission by mosquitoes, mediated exclusively by the sexual stages, i.e. male, and female gametocytes, ingested from infected vertebrate host. Studies over several decades have established antigens in the parasite sexual stages developing in the mosquito midgut as attractive targets for the development of transmission blocking vaccines (TBVs). Immune clearance of gametocytes in the vertebrate host can synergize with TBVs and directly aid in maintaining effective transmission reducing immune potential.

Indexed as

MalariaMalaria VaccinesMosquito VectorsVaccine DevelopmentAnimalsHumansPlasmodiumMalaria Vaccinescombination vaccinesMalariaopsono-phagocytosisPlasmodium falciparumPlasmodium vivaxtransmission blocking immunitytransmission blocking vaccine

Identifiers

PMID38888098
PMCPMC11472754

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.